Analysis of clinical and virological fac
β
Dr. J. A. Garson; K. Whitby; R. Deaville; S. Brillanti; M. Foli; C. Masci; M. Mi
π
Article
π
1995
π
John Wiley and Sons
π
English
β 508 KB
## Abstract Interferon alpha (IFNβΞ±) therapy is currently the treatment of choice for chronic hepatitis C (HCV) infection, but it fails to achieve a sustained response in approximately 75% of those treated. The factors which determine whether or not an individual will respond to IFNβΞ± are uncertain